Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Cancer susceptibility of beta HPV49 E6 and E7 transgenic mice to 4-nitroquinoline 1-oxide treatment correlates with mutational signatures of tobacco exposure.

Viarisio D, Robitaille A, Müller-Decker K, Flechtenmacher C, Gissmann L, Tommasino M.

Virology. 2019 Sep 24;538:53-60. doi: 10.1016/j.virol.2019.09.010. [Epub ahead of print]

PMID:
31569015
2.

Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice.

Viarisio D, Müller-Decker K, Accardi R, Robitaille A, Dürst M, Beer K, Jansen L, Flechtenmacher C, Bozza M, Harbottle R, Voegele C, Ardin M, Zavadil J, Caldeira S, Gissmann L, Tommasino M.

PLoS Pathog. 2018 Jan 11;14(1):e1006783. doi: 10.1371/journal.ppat.1006783. eCollection 2018 Jan.

3.

Human papillomaviruses and carcinogenesis: well-established and novel models.

Viarisio D, Gissmann L, Tommasino M.

Curr Opin Virol. 2017 Oct;26:56-62. doi: 10.1016/j.coviro.2017.07.014. Epub 2017 Aug 3. Review.

PMID:
28778034
4.

Correction: E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice.

Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Gröne HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M.

PLoS Pathog. 2016 Oct 28;12(10):e1006005. doi: 10.1371/journal.ppat.1006005. eCollection 2016 Oct.

5.

The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.

Viarisio D, Müller-Decker K, Hassel JC, Alvarez JC, Flechtenmacher C, Pawlita M, Gissmann L, Tommasino M.

J Invest Dermatol. 2017 Jan;137(1):261-264. doi: 10.1016/j.jid.2016.08.030. Epub 2016 Sep 17. No abstract available.

6.

Novel ß-HPV49 Transgenic Mouse Model of Upper Digestive Tract Cancer.

Viarisio D, Müller-Decker K, Zanna P, Kloz U, Aengeneyndt B, Accardi R, Flechtenmacher C, Gissmann L, Tommasino M.

Cancer Res. 2016 Jul 15;76(14):4216-25. doi: 10.1158/0008-5472.CAN-16-0370. Epub 2016 May 23.

7.

Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.

López-Toledo G, Schädlich L, Alonso-Castro ÁJ, Monroy-García A, García-Rocha R, Guido MC, Gissmann L, García-Carrancá A.

Viral Immunol. 2016 Jun;29(5):276-87. doi: 10.1089/vim.2015.0080. Epub 2016 Apr 8.

PMID:
27058179
8.

Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development.

Kumar A, Hussain S, Sharma G, Mehrotra R, Gissmann L, Das BC, Bharadwaj M.

Sci Rep. 2015 Oct 28;5:15751. doi: 10.1038/srep15751.

9.

Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.

Lei J, Osen W, Gardyan A, Hotz-Wagenblatt A, Wei G, Gissmann L, Eichmüller S, Löchelt M.

PLoS One. 2015 Sep 23;10(9):e0138458. doi: 10.1371/journal.pone.0138458. eCollection 2015.

10.

HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening.

Höfler D, Böhmer G, von Wasielewski R, Neumann H, Halec G, Holzinger D, Dondog B, Gissmann L, Pawlita M, Schmitt M.

Gynecol Oncol. 2015 Sep;138(3):676-82. doi: 10.1016/j.ygyno.2015.06.039. Epub 2015 Jul 3.

PMID:
26148764
11.

Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes.

Kumar A, Hussain S, Yadav IS, Gissmann L, Natarajan K, Das BC, Bharadwaj M.

J Virol Methods. 2015 Jun 15;218:51-8. doi: 10.1016/j.jviromet.2015.03.008. Epub 2015 Mar 21.

PMID:
25800725
12.

Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients.

Gaiser MR, Textor S, Senger T, Schädlich L, Waterboer T, Kaufmann AM, Süsal C, Pawlita M, Enk AH, Gissmann L, Lonsdorf AS.

J Dermatol Sci. 2015 Jan;77(1):37-45. doi: 10.1016/j.jdermsci.2014.11.002. Epub 2014 Nov 18.

PMID:
25439730
13.

[Vaccination against HPV-associated neoplasias].

Gross G, Becker N, Brockmeyer NH, Esser S, Freitag U, Gebhardt M, Gissmann L, Hillemanns P, Grundhewer H, Ikenberg H, Jessen H, Kaufmann A, Klug S, Klussmann JP, Nast A, Pathirana D, Petry KU, Pfister H, Röllinghof U, Schneede P, Schneider A, Selka E, Singer S, Smola S, Sporbeck B, von Knebel Doeberitz M, Wutzler P; Paul-Ehrlich-Gesellschaft für Chemotherapie e. V.

Laryngorhinootologie. 2014 Dec;93(12):848-56. doi: 10.1055/s-0034-1382013. Epub 2014 Dec 1. German. No abstract available.

PMID:
25437625
14.

Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).

Almajhdi FN, Senger T, Amer HM, Gissmann L, Öhlschläger P.

PLoS One. 2014 Nov 25;9(11):e113461. doi: 10.1371/journal.pone.0113461. eCollection 2014.

15.

Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M; Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group.

J Pathol. 2014 Dec;234(4):441-51. doi: 10.1002/path.4405. Epub 2014 Sep 12.

PMID:
25043390
16.

Helicobacter pylori antibody patterns in Germany: a cross-sectional population study.

Michel A, Pawlita M, Boeing H, Gissmann L, Waterboer T.

Gut Pathog. 2014 Apr 26;6:10. doi: 10.1186/1757-4749-6-10. eCollection 2014.

17.

Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.

Gross G, Becker N, Brockmeyer NH, Esser S, Freitag U, Gebhardt M, Gissmann L, Hillemanns P, Grundhewer H, Ikenberg H, Jessen H, Kaufmann A, Klug S, Klußmann JP, Nast A, Pathirana D, Petry KU, Pfister H, Röllinghof U, Schneede P, Schneider A, Selka E, Singer S, Smola S, Sporbeck B, von Knebel Doeberitz M, Wutzler P.

Geburtshilfe Frauenheilkd. 2014 Mar;74(3):233-241. No abstract available.

18.

Tumor prevention in HPV8 transgenic mice by HPV8-E6 DNA vaccination.

Marcuzzi GP, Awerkiew S, Hufbauer M, Schädlich L, Gissmann L, Eming S, Pfister H.

Med Microbiol Immunol. 2014 Jun;203(3):155-63. doi: 10.1007/s00430-014-0327-4. Epub 2014 Jan 21.

PMID:
24446083
19.

Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis.

Viarisio D, Decker KM, Aengeneyndt B, Flechtenmacher C, Gissmann L, Tommasino M.

J Gen Virol. 2013 Apr;94(Pt 4):749-52. doi: 10.1099/vir.0.048991-0. Epub 2012 Dec 5.

PMID:
23223623
20.

The worldwide perspective on human papillomavirus and cervical cancer.

Kaufmann AM, Gissmann L, Schneider A.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1400-1. doi: 10.1158/1055-9965.EPI-12-0849. No abstract available.

21.

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.

Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M, Michaelis U, Roden RB, Gissmann L, Kleinschmidt JA.

PLoS One. 2012;7(6):e39741. doi: 10.1371/journal.pone.0039741. Epub 2012 Jun 27.

22.

Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer.

Halec G, Schmitt M, Dondog B, Sharkhuu E, Wentzensen N, Gheit T, Tommasino M, Kommoss F, Bosch FX, Franceschi S, Clifford G, Gissmann L, Pawlita M.

Int J Cancer. 2013 Jan 1;132(1):63-71. doi: 10.1002/ijc.27605. Epub 2012 Jul 9.

23.

Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA.

Hum Gene Ther. 2012 Jul;23(7):733-41. doi: 10.1089/hum.2011.202. Epub 2012 Apr 18.

24.

New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Gersch ED, Gissmann L, Garcea RL.

Antivir Ther. 2012;17(3):425-34. doi: 10.3851/IMP1941. Epub 2011 Nov 7. Review.

25.

Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types.

Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, Lamartine J, Sylla BS, Accardi R, Tommasino M.

J Virol. 2012 Feb;86(4):2366-70. doi: 10.1128/JVI.06579-11. Epub 2011 Dec 14.

26.

E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice.

Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Gröne HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M.

PLoS Pathog. 2011 Jul;7(7):e1002125. doi: 10.1371/journal.ppat.1002125. Epub 2011 Jul 14. Erratum in: PLoS Pathog. 2016 Oct 28;12 (10 ):e1006005.

27.

The HPV16 transcriptome in cervical lesions of different grades.

Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M.

Mol Cell Probes. 2011 Oct-Dec;25(5-6):260-5. doi: 10.1016/j.mcp.2011.05.003. Epub 2011 Jun 2.

PMID:
21664454
28.

IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization.

Accardi R, Scalise M, Gheit T, Hussain I, Yue J, Carreira C, Collino A, Indiveri C, Gissmann L, Sylla BS, Tommasino M.

Mol Cell Biol. 2011 Jun;31(11):2210-26. doi: 10.1128/MCB.00964-10. Epub 2011 Apr 11.

29.

Human papillomavirus-specific immune therapy: failure and hope.

Nieto K, Gissmann L, Schädlich L.

Antivir Ther. 2010;15(7):951-7. doi: 10.3851/IMP1665. Review.

PMID:
21041909
30.

[Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline].

Gross G, Gissmann L, Hillemanns P, Ikenberg H, Kaufmann AM, Petry KU, Pfister H, Schneede P, Schneider A, Smola S; für das HPV-Management Forum.

Dtsch Med Wochenschr. 2010 May;135(21):1083-6. doi: 10.1055/s-0030-1253704. Epub 2010 May 19. German. No abstract available.

PMID:
20486060
31.

NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction.

Textor S, Accardi R, Havlova T, Hussain I, Sylla BS, Gissmann L, Cerwenka A.

Int J Cancer. 2011 Mar 1;128(5):1104-13. doi: 10.1002/ijc.25442.

32.

Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.

Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA.

Antivir Ther. 2009;14(8):1125-37. doi: 10.3851/IMP1469.

PMID:
20032542
33.

Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns.

Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M.

Cancer Res. 2010 Jan 1;70(1):249-56. doi: 10.1158/0008-5472.CAN-09-2514. Epub 2009 Dec 22.

34.

Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Senger T, Schädlich L, Textor S, Klein C, Michael KM, Buck CB, Gissmann L.

Vaccine. 2010 Feb 10;28(6):1583-93. doi: 10.1016/j.vaccine.2009.11.048. Epub 2009 Dec 8.

PMID:
20003923
35.

The therapeutic vaccine: is it feasible?

Gissmann L, Nieto K.

Arch Med Res. 2009 Aug;40(6):493-8. doi: 10.1016/j.arcmed.2009.07.003. Epub 2009 Sep 5. Review.

PMID:
19853190
36.

HPV vaccines: preclinical development.

Gissmann L.

Arch Med Res. 2009 Aug;40(6):466-70. doi: 10.1016/j.arcmed.2009.07.002. Epub 2009 Sep 5. Review.

PMID:
19853186
37.

Preface.

Gissmann L, García Carrancá A.

Arch Med Res. 2009 Aug;40(6):427. doi: 10.1016/j.arcmed.2009.08.001. No abstract available.

PMID:
19853181
38.

Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.

Senger T, Becker MR, Schädlich L, Waterboer T, Gissmann L.

J Virol. 2009 Dec;83(24):12692-701. doi: 10.1128/JVI.01582-09. Epub 2009 Sep 30.

39.

Potato virus X coat protein fusion to human papillomavirus 16 E7 oncoprotein enhance antigen stability and accumulation in tobacco chloroplast.

Morgenfeld M, Segretin ME, Wirth S, Lentz E, Zelada A, Mentaberry A, Gissmann L, Bravo-Almonacid F.

Mol Biotechnol. 2009 Nov;43(3):243-9. doi: 10.1007/s12033-009-9195-3. Epub 2009 Jul 5.

PMID:
19579017
40.

Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.

Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R, Gissmann L, Grundhewer H, Ikenberg H, Kaufmann AM, Klusmann J, Kopp I, Pfister H, Rzany B, Schneede P, Schneider A, Smola S, Winter-Koch N, Wutzler P, Gross G.

Vaccine. 2009 Jul 23;27(34):4551-9. doi: 10.1016/j.vaccine.2009.03.086. Epub 2009 Apr 17. Review.

PMID:
19524337
41.

Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.

Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L.

J Virol. 2009 Aug;83(15):7690-705. doi: 10.1128/JVI.02588-08. Epub 2009 May 20.

42.

Enhanced papillomavirus-like particle production in insect cells.

Senger T, Schädlich L, Gissmann L, Müller M.

Virology. 2009 Jun 5;388(2):344-53. doi: 10.1016/j.virol.2009.04.004. Epub 2009 May 1.

43.

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.

Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, Ottonello S.

Vaccine. 2009 Mar 18;27(13):1949-56. doi: 10.1016/j.vaccine.2009.01.102. Epub 2009 Jan 31.

PMID:
19368776
44.

[Recurrent respiratory papillomatosis: indication for HPV vaccination?].

Pawlita M, Gissmann L.

Dtsch Med Wochenschr. 2009 Apr;134 Suppl 2:S100-2. doi: 10.1055/s-0029-1220219. Epub 2009 Apr 7. German.

PMID:
19353471
45.

Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.

Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Müller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R.

PLoS Pathog. 2009 Apr;5(4):e1000373. doi: 10.1371/journal.ppat.1000373. Epub 2009 Apr 10.

46.

Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.

Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM.

Int J Cancer. 2009 Jul 1;125(1):189-98. doi: 10.1002/ijc.24333.

47.

Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.

Schädlich L, Senger T, Kirschning CJ, Müller M, Gissmann L.

Vaccine. 2009 Mar 4;27(10):1511-22. doi: 10.1016/j.vaccine.2009.01.014. Epub 2009 Jan 25.

PMID:
19174177
48.

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

Stanley M, Gissmann L, Nardelli-Haefliger D.

Vaccine. 2008 Aug 19;26 Suppl 10:K62-7. doi: 10.1016/j.vaccine.2008.05.066. Review.

PMID:
18847558
49.

Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer.

Textor S, Dürst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A.

Int J Cancer. 2008 Nov 15;123(10):2343-53. doi: 10.1002/ijc.23733.

Supplemental Content

Loading ...
Support Center